Sehgal R, et al. - Researchers conducted the study for comparing the effectiveness and side effects of spironolactone and eplerenone in the management of ascites due to liver cirrhosis. One hundred five patients of ascites with liver cirrhosis were randomized into three groups of 35 patients each. Group I was given 100 mg of spironolactone, group II received 100 mg of eplerenone and group III received 50 mg of eplerenone. Gynecomastia occurrence in group I was 14.28%, whereas no case of gynecomastia was found in group II and group III. Hyperkalemia occurred in one patient in group I, whereas in group II and group III no patient experienced hyperkalemia. Due to liver cirrhosis, eplerenone and spironolactone are equally effective in management of ascites but side effect profile of eplerenone scores over spironolactone.